The uncharted role of HER2 mutant alleles in breast cancer

Oncotarget. 2023 Oct 31;14:904-907. doi: 10.18632/oncotarget.28489.ABSTRACTSomatic HER2 mutations are a novel class of therapeutic targets across different cancer types. Treatment with the tyrosine kinase inhibitor (TKI) neratinib as a single agent continues to be evaluated in HER2-mutant metastatic disease. However, responses are heterogeneous, with frequent early progression. Herein, we discuss the under-explored effects of individual HER2 mutant alleles on therapeutic response, a role for HER2 mutation in metastatic propensity, and differences in patient outcomes in ER+ invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC). The preclinical efficacy of additional agents is also discussed, particularly the pan-HER inhibitor poziotinib.PMID:37921670 | PMC:PMC10624202 | DOI:10.18632/oncotarget.28489
Source: Oncotarget - Category: Cancer & Oncology Authors: Source Type: research